Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds - ABC News

Semaglutide is the main ingredient in Wegovy and Ozempic. A recent study found it may help reduce the risk of heart attack and stroke in people without diabetes.
Semaglutide is the main ingredient in medications including Wegovy and Ozempic.
ABC News’ Dr. Jennifer Ashton explains a new study in the New England Journal of Medicine that shows a reduction in heart attacks, strokes and death in overweight or obese participants who took semaglutide.

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

How medications like Ozempic are revolutionizing the weight loss industry

Wegovy study: Semaglutide reduced risks for heart attacks, strokes - UCHealth Today

New study shows benefits of afternoon exercise for Type 2 diabetes –

Video Semaglutide associated with lower suicide risk compared to similar drugs - ABC News

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial, Cardiovascular Diabetology

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6

Remote Health Solutions

Remote Health Solutions

Semaglutide For Weight Loss: Risks, Side Effects And More – Forbes Health

Remote Health Solutions

greenscreen #news #update #novonordisk published the #selecttrial #se